Abiopharma

🔍 CASPER MARC N (Director)

Company: THERMO FISHER SCIENTIFIC INC. (TMO)

Report Date: 2025-10-24

Detailed Transactions and Holdings:

• Acquired 17,104 shares of Common Stock at $253.99 per share (Direct)
  Date: 2025-10-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 130,866.29 | transaction_form_type: 4
• Sold 1,249 shares of Common Stock at $571.3 per share (Direct)
  Date: 2025-10-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 129,617.29 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,469 shares of Common Stock at $572.28 per share (Direct)
  Date: 2025-10-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 127,148.29 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 4,762 shares of Common Stock at $573.37 per share (Direct)
  Date: 2025-10-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 122,386.29 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 7,331 shares of Common Stock at $574.2 per share (Direct)
  Date: 2025-10-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 115,055.29 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 1,293 shares of Common Stock at $575.02 per share (Direct)
  Date: 2025-10-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 113,762.29 | transaction_form_type: 4 | Footnotes: F1, F6
• Acquired 7,250 shares of Common Stock at $253.99 per share (Direct)
  Date: 2025-10-27 | Code: M | equity_swap_involved: 0 | shares_owned_after: 121,012.29 | transaction_form_type: 4
• Sold 109 shares of Common Stock at $561.68 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 120,903.29 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 241 shares of Common Stock at $562.63 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 120,662.29 | transaction_form_type: 4 | Footnotes: F1, F8
• Sold 1,193 shares of Common Stock at $563.72 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 119,469.29 | transaction_form_type: 4 | Footnotes: F1, F9
• Sold 2,513 shares of Common Stock at $564.44 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 116,956.29 | transaction_form_type: 4 | Footnotes: F1, F10
• Sold 937 shares of Common Stock at $565.47 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 116,019.29 | transaction_form_type: 4 | Footnotes: F1, F11
• Sold 181 shares of Common Stock at $566.47 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 115,838.29 | transaction_form_type: 4 | Footnotes: F1, F12
• Sold 141 shares of Common Stock at $567.57 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 115,697.29 | transaction_form_type: 4 | Footnotes: F1, F13
• Sold 189 shares of Common Stock at $568.98 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 115,508.29 | transaction_form_type: 4 | Footnotes: F1, F14
• Sold 670 shares of Common Stock at $569.93 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 114,838.29 | transaction_form_type: 4 | Footnotes: F1, F15
• Sold 728 shares of Common Stock at $570.91 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 114,110.29 | transaction_form_type: 4 | Footnotes: F1, F16
• Sold 348 shares of Common Stock at $571.99 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 113,762.29 | transaction_form_type: 4 | Footnotes: F1, F17
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-10-24 | Code: H | nature_of_ownership: By Alison Casper 2020 Irrevocable Trust | shares_owned_after: 11,300.00 | Footnotes: F18
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-10-24 | Code: H | nature_of_ownership: By Floral Park Associates, Inc. | shares_owned_after: 14,608.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-10-24 | Code: H | nature_of_ownership: By MNC 2020 Irrevocable Trust | shares_owned_after: 5,000.00 | Footnotes: F19
• Sold 17,104 shares of Stock Option (Right to Buy) at $253.99 per share (Derivative)
  Date: 2025-10-24 | Code: M | Expires: 2026-02-26 | equity_swap_involved: 0 | shares_owned_after: 7,250.00 | transaction_form_type: 4 | Footnotes: F20
• Sold 7,250 shares of Stock Option (Right to Buy) at $253.99 per share (Derivative)
  Date: 2025-10-27 | Code: M | Expires: 2026-02-26 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F20

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.73 to $571.72, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16) and (17) to this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.75 to $572.74, inclusive.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.75 to $573.74, inclusive.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.76 to $574.75, inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.76 to $575.67, inclusive.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $561.04 to $561.97, inclusive.
• F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $562.07 to $563.02, inclusive.
• F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $563.08 to $564.07, inclusive.
• F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $564.08 to $565.07, inclusive.
• F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.08 to $565.97, inclusive.
• F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $566.14 to $566.68, inclusive.
• F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.14 to $568.13, inclusive.
• F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.32 to $569.27, inclusive.
• F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.42 to $570.41, inclusive.
• F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.43 to $571.39, inclusive.
• F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.48 to $572.27, inclusive.
• F18: The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
• F19: The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
• F20: The option vests in four equal annual installments beginning on February 26, 2020.